New therapeutic agents in ovarian cancer
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Obstetrics and Gynaecology
Reference93 articles.
1. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004);du Bois;Ann Oncol,2005
2. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma;Rose;Gynecol Oncol,2005
3. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO;Sehouli;Cancer Chemother Pharmacol,2008
4. Weekly paclitaxel in the adjuvant treatment of breast cancer;Sparano;N Engl J Med,2008
5. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840;Seidman;J Clin Oncol,2008
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. ANALYSIS OF TUMOUR VASCULARIZATION BY MICROVESSEL DENSITY AND ITS PROGNOSTIC SIGNIFICANCE IN SURFACE EPITHELIAL OVARIAN NEOPLASMS;INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH;2022-09-01
2. Antitumor effects of cecropin B-LHRH’ on drug-resistant ovarian and endometrial cancer cells;BMC Cancer;2016-03-28
3. The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer;Clinica Chimica Acta;2014-09
4. Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways;Journal of Oncology;2012
5. Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application;Journal of Oncology;2012
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3